{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:15:43Z","timestamp":1791256543932,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T00:00:00Z","timestamp":1362441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T00:00:00Z","timestamp":1362441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1038\/leu.2013.70","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T07:44:29Z","timestamp":1362469469000},"page":"1316-1321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":197,"title":["Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib"],"prefix":"10.1038","volume":"27","author":[{"given":"T D","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Grille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F E","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Levato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F J","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Dombret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Mirault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Labussi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Lindhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Haverkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Buschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"D\u00f6rken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P D","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,5]]},"reference":[{"key":"BFleu201370_CR1","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2010; 362: 2260\u20132270.","journal-title":"New Engl J Med"},{"key":"BFleu201370_CR2","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New Engl J Med 2010; 362: 2251\u20132259.","journal-title":"New Engl J Med"},{"key":"BFleu201370_CR3","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","volume":"30","author":"S Branford","year":"2012","unstructured":"Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol 2012; 30: 4323\u20134329.","journal-title":"J Clin Oncol"},{"key":"BFleu201370_CR4","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197\u20132203.","journal-title":"Leukemia"},{"key":"BFleu201370_CR5","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1161\/CIRCULATIONAHA.106.174526","volume":"113","author":"AT Hirsch","year":"2006","unstructured":"Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL et al. ACC\/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery\/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC\/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113: e463\u2013e654.","journal-title":"Circulation"},{"key":"BFleu201370_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1161\/CIR.0b013e31823299a1","volume":"125","author":"MA Creager","year":"2012","unstructured":"Writing Committee to Develop Clinical Data Standards for Peripheral Atherosclerotic Vascular D Creager MA, Belkin M, Bluth EI, Casey DE Jr., Chaturvedi S et al2012 ACCF\/AHA\/ACR\/SCAI\/SIR\/STS\/SVM\/SVN\/SVS key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Peripheral Atherosclerotic Vascular Disease). Circulation 2012; 125: 395\u2013467.","journal-title":"Circulation"},{"key":"BFleu201370_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"KJ Aichberger","year":"2011","unstructured":"Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86: 533\u2013539.","journal-title":"Am J Hematol"},{"key":"BFleu201370_CR8","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djr292","volume":"103","author":"P Le Coutre","year":"2011","unstructured":"Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011; 103: 1347\u20131348.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201370_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","volume":"12","author":"A Quintas-Cardama","year":"2012","unstructured":"Quintas-Cardama A, Kantarjian H, Cortes J . Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012; 12: 337\u2013340.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFleu201370_CR10","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/ajh.22051","volume":"86","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Letendre L . Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011; 86: 610\u2013611.","journal-title":"Am J Hematol"},{"key":"BFleu201370_CR11","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.jacc.2011.08.023","volume":"58","author":"TW Rooke","year":"2011","unstructured":"Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK et al2011 ACCF\/AHA focused update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 58: 2020\u20132045.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"BFleu201370_CR12","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2013.69","volume":"27","author":"F J Giles","year":"2013","unstructured":"Giles FJ, Mauro MJ, Hong F, Ortmann C-E, McNeill C, Woodman RC et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013; e-pub ahead of print 5 March 2013 doi:10.1038\/leu.2013.69.","journal-title":"Leukemia"},{"issue":"6","key":"BFleu201370_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/ejh.12096","volume":"90","author":"Luciano Levato","year":"2013","unstructured":"Levato L, Cantaffa R, Kropp M, Magro D, Piro E, Molica S . Progressive peripheral arterial occlusive disease and other vascular events during Nilotinib therapy in chronic myeloid leukemia: A single institution study. Eur J Haematol 2013; e-pub ahead of print 18 March 2013 doi:10.1111\/ejh.12096.","journal-title":"European Journal of Haematology"},{"key":"BFleu201370_CR14","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/02841860903229124","volume":"48","author":"GS Orphanos","year":"2009","unstructured":"Orphanos GS, Ioannidis GN, Ardavanis AG . Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009; 48: 964\u2013970.","journal-title":"Acta Oncol"},{"key":"BFleu201370_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/1078155210378913","volume":"17","author":"NM Agostino","year":"2011","unstructured":"Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 2011; 17: 197\u2013202.","journal-title":"J Oncol Pharm Pract"},{"key":"BFleu201370_CR16","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1210\/jc.2010-0086","volume":"95","author":"S Fitter","year":"2010","unstructured":"Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC . Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab 2010; 95: 3763\u20133767.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFleu201370_CR17","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.leukres.2009.02.024","volume":"33","author":"R Gologan","year":"2009","unstructured":"Gologan R, Constantinescu G, Georgescu D, Ostroveanu D, Vasilache D, Dobrea C et al. Hypolipemiant besides antileukemic effect of imatinib mesylate. Leuk Res 2009; 33: 1285\u20131287.","journal-title":"Leuk Res"},{"key":"BFleu201370_CR18","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1161\/01.ATV.0000124105.39900.db","volume":"24","author":"M Lassila","year":"2004","unstructured":"Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R et al. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 935\u2013942.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFleu201370_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2458-10-38","volume":"10","author":"MT Alzamora","year":"2010","unstructured":"Alzamora MT, Fores R, Baena-Diez JM, Pera G, Toran P, Sorribes M et al. The peripheral arterial disease study (PERART\/ARTPER): prevalence and risk factors in the general population. BMC Public Health 2010; 10: 38.","journal-title":"BMC Public Health"},{"key":"BFleu201370_CR20","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1093\/eurheartj\/ehl228","volume":"27","author":"C Lamina","year":"2006","unstructured":"Lamina C, Meisinger C, Heid IM, Lowel H, Rantner B, Koenig W et al. Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. Eur Heart J 2006; 27: 2580\u20132587.","journal-title":"Eur Heart J"},{"key":"BFleu201370_CR21","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1161\/01.CIR.0000137913.26087.F0","volume":"110","author":"E Selvin","year":"2004","unstructured":"Selvin E, Erlinger TP . Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110: 738\u2013743.","journal-title":"Circulation"},{"issue":"15_suppl","key":"BFleu201370_CR22","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1200\/jco.2010.28.15_suppl.6501","volume":"28","author":"R. A. Larson","year":"2010","unstructured":"Larson RA, Le Coutre P, Reiffers J, Hughes TP, Saglio G, Edrich P et al. Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year. J Clin Oncol 2010; 28(suppl): abstr. 6501.","journal-title":"Journal of Clinical Oncology"},{"key":"BFleu201370_CR23","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0002-9440(10)63716-9","volume":"164","author":"N Ferri","year":"2004","unstructured":"Ferri N, Carragher NO, Raines EW . Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis. Am J Pathol 2004; 164: 1575\u20131585.","journal-title":"Am J Pathol"},{"key":"BFleu201370_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129\u2013141.","journal-title":"Cancer Cell"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201370","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:33:22Z","timestamp":1648744402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,5]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["BFleu201370"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.70","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,5]]},"assertion":[{"value":"12 February 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TDK, MS, PG, LL, HD, TM, HL, RL, WH, IB and BD declare no conflict of interest. DR received honoraria from Teva, Novartis and BMS. FEN was a consultant for Novartis, Ariad and Teva. He received lecture fees from BMS, Novartis, Ariad and Teva and received advisory board honoraria from Novartis, Ariad, Teva and Pfizer. GR received honoraria from Novartis, BMS, Pfizer and Roche. FJG is a consultant for and received research funding from Novartis. PDLC received honoraria from Novartis, BMS, Pfizer and Ariad. He also received research funding from Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}